Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy

European Urology

Volumn 29, Issue 1, 1996, Pages 29-35

  Lukacs, B ^a   Blondin, P ^a   MacCarthy, C ^a   Du Boys, B ^a   Grippon, P ^a   Lassale, C ^a  

^a Synthelabo Recherche   (United Kingdom)

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Safety profile

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT;

ABDOMINAL PAIN; ADULT; AGE; AGED; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SKIN DISEASE; SYNCOPE; URINARY TRACT DISEASE; VERTIGO; VOMITING;

EID: 0030058397     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000473714     Document Type: Article

References (0)